These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36715286)

  • 21. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.
    Kosche C; Stout M; Sosman J; Lukas RV; Choi JN
    Melanoma Res; 2020 Jun; 30(3):313-316. PubMed ID: 31567590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Life-threatening flare of an underlying «paraneoplastic» dermatomyositis in a patient with lung adenocarcinoma treated with anti-PD-1 pembrolizuma].
    Chauveheid F; von Frenckell C; Colin G; Deflandre E; Piette Y; Duysinx B; Bianchi E; Malaise M; Malaise O
    Rev Med Liege; 2022 Jul; 77(7-8):462-467. PubMed ID: 35924504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature.
    Veccia A; Kinspergher S; Grego E; Peterlana D; Berti A; Tranquillini E; Caffo O
    Anticancer Drugs; 2020 Jun; 31(5):540-544. PubMed ID: 32011360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
    Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
    J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
    Messer A; Drozd B; Glitza IC; Lu H; Patel AB
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-TIF1γ antibody predicted malignancy of thymic tumor with dermatomyositis as an "autoimmune tumor marker": A case report.
    Karino K; Fujieda Y; Kawamura T; Abe N; Shimoyama S; Kono M; Kato M; Yasuda S; Atsumi T
    Medicine (Baltimore); 2018 Dec; 97(49):e13563. PubMed ID: 30544475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
    Kotobuki Y; Tonomura K; Fujimoto M
    Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
    Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
    Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
    Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
    Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-TIF1γ antibody-positive dermatomyositis in a 15-year-old boy with Epstein-Barr virus-related nasopharyngeal cancer receiving nivolumab.
    Asano R; Shinoda K; Tsuda R; Hounoki H; Kawataka M; Makino T; Imura J; Hamaguchi Y; Tobe K
    Rheumatology (Oxford); 2021 Jun; 60(6):e197-e199. PubMed ID: 33367923
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
    Suga T; Oiwa H; Ishida M; Iwamoto Y
    Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
    Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
    Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma.
    Yamaguchi Y; Aso M; Nagasawa H; Wada M
    Intern Med; 2021 Sep; 60(18):3025-3029. PubMed ID: 33776010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.
    Pinal-Fernandez I; Ferrer-Fabregas B; Trallero-Araguas E; Balada E; Martínez MA; Milisenda JC; Aparicio-Español G; Labrador-Horrillo M; Garcia-Patos V; Grau-Junyent JM; Selva-O'Callaghan A
    Rheumatology (Oxford); 2018 Feb; 57(2):388-396. PubMed ID: 29149307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
    Guerra NL; Matas-García A; Serra-García L; Morgado-Carrasco D; Padrosa J; Aldecoa I; Duque Y; Casal-Dominguez M; Muñoz-Braceras S; Aranega R; Moreno-Lozano P; Cantó-Santos J; Garrabou G; Ruiz-Ortiz E; Trallero-Araguas E; Selva-O'Callaghan A; Grau JM; Puig S; Torres-Ruiz J; Mammen AL; Fernandez IP; Milisenda JC
    Autoimmun Rev; 2023 Aug; 22(8):103375. PubMed ID: 37321468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features of anti-transcription intermediary factor 1γ (TIF1γ)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1γ expression in tumors in the pathogenesis of cancer-associated dermatomyositis.
    Motegi SI; Sekiguchi A; Ikeuchi H; Sakairi T; Ogawa H; Fujii T; Sohda M; Yajima T; Ida S; Takayasu Y; Shimoda Y; Hiromura K; Saeki H; Shirabe K; Chikamatsu K; Yokoo H; Oyama T; Ishikawa O
    J Dermatol; 2020 Dec; 47(12):1395-1402. PubMed ID: 32734678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
    Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
    Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3.
    Chin K; Yamamoto S; Takahashi M; Kadowaki S; Kubota Y; Amanuma Y; Okada M; Kanda M; Kimura Y; Nogi Y; Arimitsu Y; Kitagawa Y
    Esophagus; 2023 Apr; 20(2):302-308. PubMed ID: 36564602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
    Venalis P; Selickaja S; Lundberg K; Rugiene R; Lundberg IE
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):648-651. PubMed ID: 28704599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.